#4-89E. Breaking the Steroid Dependence: The Role of IL-5 Inhibitors in EGPA Management (Arthritis Rheumatol, 2026)

How can we effectively manage eosinophilic granulomatosis with polyangiitis (EGPA) while minimizing the severe long-term complications of glucocorticoid dependence? This episode delves into a comprehensive review detailing the crucial role of interleukin-5 (IL-5) in driving eosinophil maturation, activation, and survival in EGPA pathogenesis1. The paper highlights the clinical efficacy and safety of IL-5 pathway inhibitors, such as mepolizumab and benralizumab, demonstrating their remarkable ability to reduce relapse rates and facilitate significant glucocorticoid tapering. The most critical clinical takeaway is that these targeted therapies can achieve sustained remission and even complete steroid withdrawal in a substantial proportion of patients. However, when critically appraising these findings, clinicians must note that the major clinical trials primarily included patients with low ANCA positivity and predominant asthmatic features, leaving their efficacy against severe vasculitic manifestations—like neuropathy or cardiac involvement—less certain. For listening physicians, this review is essential as it provides actionable evidence to transition steroid-dependent EGPA patients to safer, targeted biologic therapies, fundamentally changing day-to-day management strategies to improve patient outcomes48.

Citation: Berti A, Pagnoux C. Interleukin-5, Eosinophils, and Interleukin-5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 78(6), 1196-1205, 2026. DOI: 10.1002/art.43409

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.